1 Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights IND Submission for CR-001, a PD-1 x VEGF Bispecific Antibody, on Track for Fourth Quarter of 2025 to Support Initiation of Global Phase 1 Trial in Patients with Solid Tumors Advancing ADCs in the Pipeline, with IND Submission for CR-002 on Track for Mid-2026 Waltham, Mass., November 6, 2025 – Crescent Biopharma, Inc. ("Crescent" or the "Company") (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advan ...

INTERNATIONAL SEAWAYS REPORTS THIRD QUARTER 2025 RESULTS New York, NY – November 6, 2025– International Seaways, Inc. (NYSE: INSW) (the "Company," "Seaways," or "INSW"), one of the largest tanker companies worldwide providing energy transportation services for crude oil and petroleum products, today reported results for the third quarter 2025. HIGHLIGHTS & RECENT DEVELOPMENTS Quarterly Results: Fleet Optimization Program: Healthy Balance Sheet: Exhibit 99.1 Returns to Shareholders: · Net income for the thir ...

Exhibit 99.1 PublicSquare Delivers Strong Third Quarter Financial Results & Beats Revenue Guidance by 10% Reaffirms Fourth Quarter 2025 & Full Year 2026 Revenue Guidance Fintech Revenue Increased 28% Quarter Over Quarter Credit Revenue Increased 22% Quarter Over Quarter Payments Revenue Increased 50% Quarter Over Quarter WEST PALM BEACH, FL, November 6, 2025 — PSQ Holdings, Inc. (NYSE: PSQH) ("PublicSquare," or the "Company"), today reported financial results for the third quarter 2025. THIRD QUARTER 2025 H ...

Financial Performance - For the three months ended September 30, 2025, revenue increased to $144.2 million, up 17.1% from $123.1 million in the same period of 2024[127] - Pre-tax income attributable to controlling interests for the three months ended September 30, 2025, was $22.5 million, a decrease of 14.4% compared to $26.3 million in 2024[127] - Economic net income (ENI) for the three months ended September 30, 2025, was $27.2 million, representing a 22.5% increase from $22.2 million in 2024[127] - Total revenue for the three months ended September 30, 2025, was $144.2 million, an increase of $21.1 million, or 17.1%, from $123.1 million in 2024[143] - Net income for the three months ended September 30, 2025, was $27.0 million, an increase of $8.0 million, or 42.1%, from $19.0 million in 2024[143] - U.S. GAAP operating income for the nine months ended September 30, 2025 was $74.7 million, compared to $70.5 million for the same period in 2024, reflecting a growth of 3.0%[182] - Total revenue for the nine months ended September 30, 2025 was $391.5 million, up from $337.8 million in 2024, representing a 15.9% increase[182] - Economic net income (ENI) for the nine months ended September 30, 2025 was $70.4 million, compared to $56.8 million in 2024, indicating a 24.8% increase[189] Assets Under Management (AUM) - Assets under management (AUM) at period end reached $166.4 billion, an increase of 38.3% from $120.3 billion in 2024[127] - Total assets under management (AUM) increased to $166.4 billion as of September 30, 2025, up by $46.1 billion or 38.3% from $120.3 billion a year earlier[130][138] - AUM by strategy as of September 30, 2025: Non-U.S. Equity at $35.3 billion (21.2%), Enhanced Equity at $34.2 billion (20.6%), and Small Cap Equity at $31.7 billion (19.1%)[131] - Institutional clients accounted for $135.0 billion or 81.1% of total AUM as of September 30, 2025, compared to $93.0 billion or 79.3% as of December 31, 2024[132] - AUM from U.S. clients was $94.5 billion, representing 56.8% of total AUM as of September 30, 2025, compared to $74.7 billion or 63.7% a year earlier[133] - AUM from EMEA clients increased to $36.4 billion (21.9%) as of September 30, 2025, up from $16.9 billion (14.4%) as of December 31, 2024[133] - The company reported a beginning balance of $151.1 billion for total AUM as of June 30, 2025, with an ending balance of $166.4 billion[138] - The increase in AUM was driven by equity market appreciation and positive net client cash flows over the last twelve months[138] Client Cash Flows - Net client cash flows for the three months ended September 30, 2025, were $6.4 billion, significantly up from $0.5 billion in the same period of 2024, reflecting a $5.9 billion increase[127] - Net client cash flows for the three months ended September 30, 2025, were $6.4 billion, with gross inflows of $11.9 billion and gross outflows of $6.5 billion[134] - For the nine months ended September 30, 2025, net inflows reached $24.0 billion compared to $0.9 billion in 2024, driven by strong gross inflows of $39.4 billion[140] Revenue and Fees - ENI revenue for the three months ended September 30, 2025, was $136.3 million, a 11.5% increase from $122.2 million in 2024[127] - Management fees for the three months ended September 30, 2025, increased by $24.0 million, or 21.4%, to $136.1 million, attributed to a 34.5% rise in average assets under management[149] - Average assets under management for the three months ended September 30, 2025, were $156.5 billion, up from $116.4 billion in 2024[149] - Performance fees for the three months ended September 30, 2025, decreased by $9.9 million, or 98.0%, to $0.2 million due to changes in performance relative to benchmarks[153] - Management fees contributed $136.1 million to ENI revenue in Q3 2025, up from $112.1 million in Q3 2024, marking a 21.4% increase[192] Operating Expenses and Compensation - The U.S. GAAP operating margin for the three months ended September 30, 2025, was 18.4%, down 349 basis points from 21.9% in 2024[127] - Average basis points earned on average assets under management decreased to 34.5 bps for the three months ended September 30, 2025, from 38.3 bps in 2024[148] - For the three months ended September 30, 2025, total variable compensation increased to $31.8 million, up 8.2% from $29.4 million in the same period of 2024[161] - Compensation and benefits expense rose by $15.1 million, or 21.7%, from $69.6 million for the three months ended September 30, 2024 to $84.7 million for the same period in 2025[161] - General and administrative expenses increased by $1.7 million, or 7.8%, from $21.8 million for the three months ended September 30, 2024 to $23.5 million for the same period in 2025[163] - Variable compensation for the nine months ended September 30, 2025 was $93.6 million, up from $83.7 million in 2024, reflecting a 11.9% increase[183] Tax and Interest - Income tax expense decreased by $2.0 million, from $9.4 million for the three months ended September 30, 2024 to $7.4 million for the same period in 2025[176] - The effective tax rate on economic net income for Q3 2025 is 28.0%, compared to 31.9% in Q3 2024[203] - Interest income increased by $0.3 million, or 50.0%, from $0.6 million for the three months ended September 30, 2024 to $0.9 million for the same period in 2025[169] Debt and Financing - On October 30, 2025, the company issued a notice for the full redemption of all $275 million aggregate principal amount outstanding of its 4.80% Senior Notes due July 27, 2026[228] - Acadian LLC has a delayed draw term loan facility of up to $200 million, maturing on October 28, 2028, with the potential to increase to $275 million[236] - The company plans to use proceeds from the term facility to fund the redemption of its $275 million 2026 Notes[237] - The financial covenants require a maximum Consolidated Net Leverage Ratio of 2.5x and a minimum Consolidated Interest Coverage Ratio of 4.0x[239] Market Sensitivity - A 10% change in foreign exchange rates against the U.S. dollar could lead to a change in annualized management fee revenue of $46 million and an annual change in post-tax economic net income of $18 million[260] - A 10% increase or decrease in equity markets would result in a change in annualized management fee revenue of $57 million and an annual change in post-tax economic net income of approximately $22 million[260] - Approximately 13% of AUM, or $22 billion, are in accounts subject to performance fees, with a 10% change in AUM affecting performance fees by about $6 million[255] Cash Flow - Net cash from operating activities increased by $4.4 million, from $59.1 million in the nine months ended September 30, 2024 to $63.5 million in 2025[223] - Net cash from investing activities changed by $57.0 million, from $(48.3) million in 2024 to $8.7 million in 2025[223] Other Financial Metrics - The Leverage Ratio as of September 30, 2025 was 0.0x, indicating no third-party borrowings relative to trailing twelve months Adjusted EBITDA[233] - Acadian LLC recorded accrued incentive compensation of $96.2 million as of September 30, 2025, down from $119.6 million as of December 31, 2024[246] - Approximately 39% of Acadian LLC's ENI cost structure is variable, linked to the profitability of the business after covering operating expenses[254]

Revenue Performance - Revenue for the three months ended September 30, 2025, was $14.7 million, an increase of $1.3 million, or 10%, compared to the same period in 2024[86] - Revenue for the nine months ended September 30, 2025, was $40.6 million, an increase of $4.7 million, or 13%, compared to the same period in 2024[99] - Revenue generated in the U.S. was $36.9 million for the nine months ended September 30, 2025, an increase of $4.1 million, or 13%, over the prior year[100] - Revenue generated in Europe was $3.7 million for the nine months ended September 30, 2025, a $0.5 million increase, or 17%, compared to the same period in 2024[101] Gross Profit and Margins - Gross profit increased to $12.8 million for the three months ended September 30, 2025, a rise of $1.6 million, or 15%, with a gross margin of 87% compared to 83% in the prior year[91] - Gross profit for the nine months ended September 30, 2025, was $34.5 million, reflecting a $4.3 million increase, or 14%, over the prior year[103] Operating Expenses - Total operating expenses for the three months ended September 30, 2025, were $25.0 million, an increase of $0.9 million, or 4%, compared to the same period in 2024[85] - SG&A expenses decreased by $4.6 million, or 6%, to $66.5 million for the nine months ended September 30, 2025, primarily due to a decrease in non-cash stock-based compensation[107] Research and Development - Research and development expenses rose to $3.1 million, an increase of $0.6 million, or 26%, primarily due to higher compensation and consulting costs[92] Net Loss - Net loss for the nine months ended September 30, 2025, was $41.4 million, a decrease of $7.9 million, or 16%, compared to the net loss of $49.3 million in the same period in 2024[111] - The company anticipates continued net losses in the coming years due to planned investments in commercialization efforts[72] Cash and Financing - The company had cash and cash equivalents of $85.1 million as of September 30, 2025, down from $105.9 million at the end of 2024[111] - Cash used in operating activities for the nine months ended September 30, 2025, was $30.4 million, slightly lower than $31.1 million in the same period in 2024[118] - The company issued 543,462 shares of common stock under the ATM offering for gross proceeds of $9.5 million during the nine months ended September 30, 2025[113] - Interest expense increased by $1.5 million for the nine months ended September 30, 2025, driven by higher levels of borrowings under the Loan Agreement[108] Market Expansion and Strategy - U.S. sales accounted for $13.5 million, reflecting a 10% increase, driven by growth in the heart failure business and expansion into new sales territories[87] - The company had 250 active implanting centers in the U.S. as of September 30, 2025, up from 208 in the previous year[88] - The company plans to expand its U.S. commercial organization and increase awareness among physicians and patients to drive future revenue growth[77] Regulatory and Economic Factors - The Centers for Medicare & Medicaid Services released new Category I CPT codes for Barostim, expected to improve reimbursement predictability starting January 1, 2026[73] - Inflationary factors may adversely affect operating results, with potential impacts on gross margin and operating expenses if product selling prices do not increase accordingly[129] - Revenue and operating expenses incurred outside the U.S. are subject to foreign currency exchange rate fluctuations, particularly with the Euro, but realized gains and losses have not been material to financial statements[128] - The company is exposed to interest rate risk primarily related to cash equivalents and debt under the Loan Agreement, with no current plans to use financial derivatives[127]

Financial Performance - Climb Bio, Inc. reported net losses of $12.9 million and $42.3 million for the three and nine months ended September 30, 2025, respectively, with an accumulated deficit of $272.2 million[99]. - Net loss for the three months ended September 30, 2025, was $12.9 million, compared to a net loss of $8.9 million in the same period of 2024, reflecting an increase of $3.9 million[118]. - For the nine months ended September 30, 2025, research and development expenses surged to $33.0 million from $8.4 million in 2024, with a $13.4 million increase attributed to the budoprutug program[125]. - General and administrative expenses for the nine months ended September 30, 2025, increased by $4.5 million to $15.6 million, mainly due to a $3.1 million rise in personnel-related expenses[127]. - Total operating expenses for the nine months ended September 30, 2025, were $48.6 million, a decrease of $22.5 million from $71.1 million in 2024[124]. - Net cash used in operating activities for the nine months ended September 30, 2025, was $38.7 million, compared to $10.0 million in 2024[132]. - Interest income decreased from $2.8 million in Q3 2024 to $2.0 million in Q3 2025, primarily due to lower invested balances[121]. - As of September 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $175.8 million[130]. Research and Development - Climb Bio is developing budoprutug for three distinct immune-mediated diseases: pMN, immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE)[92]. - The company received FDA clearance for a Phase 2 clinical trial of budoprutug in primary membranous nephropathy (pMN), with 60% of patients achieving complete remission of proteinuria in a prior Phase 1b trial[93]. - Climb Bio anticipates significant increases in research and development expenses as it conducts ongoing clinical trials and studies[108]. - The company expects to have initial data from the Phase 1b/2a clinical trial in ITP in the second half of 2026[94]. - Budoprutug is designed to deplete CD19-positive B cells, potentially offering a disease-modifying approach for various immune-mediated diseases[91]. - CLYM116 is being developed for immunoglobulin A nephropathy (IgAN) and has shown improved bioavailability and prolonged exposure compared to first-generation therapies[97]. - Research and development expenses increased from $6.2 million in Q3 2024 to $9.1 million in Q3 2025, primarily due to a $2.7 million increase in costs for the budoprutug program[119]. Acquisitions and Agreements - Climb Bio acquired Tenet Medicines, Inc. for $41.9 million, with total acquisition costs amounting to $52.8 million, including transaction costs[103]. - The upfront payment for the Mabworks Agreement to develop CLYM116 was $9.0 million, with additional milestone payments and royalties expected[104]. - The company has obligations under an asset purchase agreement with Acelyrin, which includes milestone and royalty payments contingent on future events[145]. Future Funding and Financial Strategy - The company believes its existing cash, cash equivalents, and marketable securities will be sufficient to fund operations through 2027[139]. - Future funding requirements will depend on various factors, including the costs and progress of clinical trials for product candidates like budoprutug and CLYM116[142]. - The company may finance operations through equity offerings, debt financings, and collaborations, but may face dilution of stockholder ownership[140]. - The company may need to delay or limit product development if unable to raise additional funds when needed[141]. - The company is subject to risks related to unforeseen expenses and complications in the development of biopharmaceutical candidates[140]. General and Administrative Expenses - General and administrative expenses rose from $5.5 million in Q3 2024 to $5.8 million in Q3 2025, driven by higher personnel-related expenses of $0.8 million[120]. - The company has fixed lease payments of $0.4 million through December 2026, with an option to extend for an additional $0.3 million[144]. Accounting and Compliance - The company is classified as an emerging growth company and can delay adopting new accounting standards until certain revenue thresholds are met, specifically $1.235 billion[149]. - The company has not made material changes to its critical accounting policies during the three or nine months ended September 30, 2025[147].

Financial Performance - Climb Bio, Inc. reported net losses of $12.9 million and $42.3 million for the three and nine months ended September 30, 2025, respectively, with an accumulated deficit of $272.2 million[99]. - Net loss for the three months ended September 30, 2025, was $12.9 million, compared to a net loss of $8.9 million for the same period in 2024, reflecting an increase of $3.9 million[118]. - Total operating expenses for the nine months ended September 30, 2025, were $48.6 million, a decrease of $22.5 million from $71.1 million in the same period in 2024[124]. - Net cash used in operating activities for the nine months ended September 30, 2025, was $38.7 million, compared to $10.0 million in the same period in 2024[132]. - Research and development expenses for the nine months ended September 30, 2025, were $33.0 million, up from $8.4 million in 2024, primarily due to increased costs for the budoprutug and CLYM116 programs[125]. - General and administrative expenses for the nine months ended September 30, 2025, increased by $4.5 million to $15.6 million, largely due to a $3.1 million rise in personnel-related expenses[127]. Clinical Development - The company received FDA clearance for a Phase 2 clinical trial of budoprutug in primary membranous nephropathy (pMN), where 60% of patients in a prior trial achieved complete remission of proteinuria[93]. - Climb Bio is also advancing budoprutug in clinical trials for immune thrombocytopenia (ITP) and systemic lupus erythematosus (SLE), with initial data expected in the second half of 2026 for both indications[94][95]. - The company is developing CLYM116, an anti-APRIL monoclonal antibody, which has shown improved bioavailability and prolonged exposure compared to a first-generation counterpart[97]. - The company has paused the development of its Kv7 program, previously focused on neuronal excitability disorders, while seeking a partner for further development[98]. Acquisitions and Agreements - The company acquired Tenet Medicines, Inc. for $41.9 million in common stock, with total acquisition costs amounting to $52.8 million, including transaction costs[103]. - Climb Bio entered into the Mabworks Agreement, making an upfront payment of $9.0 million for rights to develop CLYM116 outside Greater China, with additional milestone payments expected[104]. - The company has obligations under an asset purchase agreement with Acelyrin, which includes milestone and royalty payments contingent on future events[145]. Financial Position and Funding - Climb Bio's cash, cash equivalents, and marketable securities are estimated to fund operations through 2027, but future financing may be required if capital resources are depleted sooner than anticipated[102]. - The company believes its existing cash, cash equivalents, and marketable securities will be sufficient to fund operations through 2027[139]. - Future funding requirements will depend on various factors, including the costs and progress of clinical trials for product candidates like budoprutug and CLYM116[142]. - The company may need to finance operations through equity offerings or debt financings, which could dilute stockholder ownership[141]. Expenses and Cost Management - Research and development expenses increased from $6.2 million in Q3 2024 to $9.1 million in Q3 2025, primarily due to a $2.7 million increase in costs for the budoprutug program[119]. - General and administrative expenses rose from $5.5 million in Q3 2024 to $5.8 million in Q3 2025, driven by higher personnel-related expenses of $0.8 million[120]. - The company is subject to risks related to biopharmaceutical development, which may lead to unforeseen expenses and delays[140]. - The company may face inflationary pressures affecting salaries, goods, and transportation costs, impacting overall expenses[142]. - The company has no material minimum purchase commitments in contracts with third parties for clinical trials and manufacturing services[143]. Compliance and Accounting - The company is classified as an emerging growth company and can delay adopting new accounting standards until they apply to private companies[149]. - The company’s financial statements are prepared in accordance with U.S. GAAP, requiring estimates that could differ materially from actual results[146].

McLean, VA – November 6, 2025 – Appian (Nasdaq: APPN) today announced financial results for the third quarter ended September 30, 2025. Exhibit 99.1 Appian Announces Third Quarter 2025 Financial Results Third quarter cloud subscriptions revenue increased 21% year-over-year to $113.6 million Third quarter total revenue increased 21% year-over-year to $187.0 million Third Quarter 2025 Financial Highlights: A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables following the fi ...

Angel Oak Mortgage REIT, Inc. Reports Third Quarter 2025 Financial Results ATLANTA – November 6, 2025 -- Angel Oak Mortgage REIT, Inc. (NYSE: AOMR) (the "Company," "we," and "our"), a leading real estate finance company focused on acquiring and investing in first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market, today reported financial results for the quarter ended September 30, 2025. Third Quarter 2025 and Year-to-Date Highlights Sreeni Prabhu, Chief Executive Officer and Pr ...

FOR IMMEDIATE RELEASE Cogent Contacts: For Public Relations: For Investor Relations: Jocelyn Johnson John Chang + 1 (202) 295-4299 + 1 (202) 295-4212 jajohnson@cogentco.com investor.relations@cogentco.com Cogent Communications Reports Third Quarter 2025 Results Exhibit 99.1 · Service revenue was $241.9 million for Q3 2025 and was $246.2 million for Q2 2025. o On-net revenue increased by 2.2% from Q2 2025 to Q3 2025. § On-net revenue was $135.3 million for Q3 2025 and $132.3 million for Q2 2025. o Wavelength ...